EG12014

BIOLOGICAL2 trials

Sponsors

EirGenix, Inc.

Conditions

Breast CancerHealthy

Phase 1

A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male Volunteers

CompletedNCT03180242

EirGenix, Inc.Healthy

Start: 2016-03-22End: 2016-08-22Updated: 2017-06-08

Phase 3

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

CompletedNCT03433313

EirGenix, Inc.Breast Cancer

Start: 2018-10-16End: 2022-01-20Updated: 2023-01-20

Related Papers

Abstract P2-13-17: A phase III, randomized, multicenter, double-blind study to compare efficacy and safety of EG12014 (EirGenix trastuzumab) with Herceptin® as neoadjuvant treatment in combination with anthracycline/paclitaxel-based systemic therapy in patients with HER2-positive early breast cancer - a multinational phase III study conducted during the COVID-19 pandemic

Cancer Research2022-02-152 citations